Cargando…
Effects of a novel combination of orlistat and acarbose on tolerability, appetite, and glucose metabolism in persons with obesity
OBJECTIVE: There is an unmet medical need for a safe and effective weight loss product with minimal systemic side‐effects. In this study, the effect of a novel modified‐release fixed‐dose combination of orlistat and acarbose (MR‐OA) was compared with conventional orlistat (CO) regarding tolerability...
Autores principales: | Holmbäck, Ulf, Forslund, Anders, Grudén, Stefan, Alderborn, Göran, Söderhäll, Arvid, Hellström, Per M., Lennernäs, Hans |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
John Wiley and Sons Inc.
2020
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7278902/ https://www.ncbi.nlm.nih.gov/pubmed/32523721 http://dx.doi.org/10.1002/osp4.405 |
Ejemplares similares
-
Safety of a Novel Weight Loss Combination Product Containing Orlistat and Acarbose
por: Grudén, Stefan, et al.
Publicado: (2021) -
Effects of a novel weight‐loss combination product containing orlistat and acarbose on obesity: A randomized, placebo‐controlled trial
por: Holmbäck, Ulf, et al.
Publicado: (2022) -
Obesity management: Update on orlistat
por: Drew, Belinda S, et al.
Publicado: (2007) -
Efficacy and Tolerability of the Association of Sibutramine and
Orlistat for Six Months in Overweight and Obese Patients
por: Halpern, Alfredo, et al.
Publicado: (2010) -
Orlistat in the prevention of diabetes in the obese patient
por: Mancini, Marcio C, et al.
Publicado: (2008)